Details of Metabolite

General Information of MET (ID: META00226)
Name Liothyronine
Synonyms   Click to Show/Hide Synonyms of This Metabolite
3,5,3'-Triiodo-L-thyronine, 3,5,3'-Triiodothyronine, 3,5,3'TRIIODOTHYRONINE, '4-(4-Hydroxy-3-iodophenoxy)-3,5-diiodo-L-phenylalanine', L-3,5,3'-Triiodothyronine, 'L-T3; Cyronine', L-3,3',5-triiodo-Thyronine, L-3,3',5-Triiodothyronine, 'L-3-[4-(4-Hydroxy-3-iodophenoxy)-3,5-diiodophenyl]-alanine; L-Liothyronine; L-Triiodothyronine; Liothyronin; Liothyronine sodium', 3,3',5'-triiodo-L-Thyronine, 3,3',5'-Triiodothyronine, '4-(4-Hydroxy-3-iodophenoxy)-3,5-diiodophenylalanine; Liothyroninum; Liotironina; O-(4-Hydroxy-3-iodophenyl)-3,5-diiodo-L-tyrosine; T3; T3 Thyroid hormone; Tertroxin; Thyroid hormone, T3; Tresitope; Triiodothyronine', 3,3',5-Triiodo-L-thyronine, 'Thyrolar', 3,3',5-Triiodothyronine, 'Cytomel; triiodo-L-Thyronine
Source Aromatic homomonocyclic compounds
Structure Type   Amino acids, peptides, and analogues  (Click to Show/Hide the Complete Structure Type Hierarchy)
Organic acids and derivatives
Carboxylic acids and derivatives
Amino acids, peptides, and analogues
PubChem CID
5920
HMDB ID
HMDB0000265
Formula
C15H12I3NO4
Structure
<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=5920"></iframe>
3D MOL 2D MOL
  Click to Show/Hide the Molecular/Functional Data (External Links/Property/Function) of This Metabolite
KEGG ID
C02465
DrugBank ID
DB00279
ChEBI ID
18258
Physicochemical Properties Molecular Weight 650.97 Topological Polar Surface Area 92.8
XlogP 1.7 Complexity 402
Heavy Atom Count 23 Rotatable Bond Count 5
Hydrogen Bond Donor Count 3 Hydrogen Bond Acceptor Count 5
Function
Liothyronine is a T3 thyroid hormone normally synthesized and secreted by the thyroid gland in much smaller quantities than thyroxine (T4). Most T3 is derived from peripheral monodeiodination of T4 at the 5' position of the outer ring of the iodothyronine nucleus. The hormone that is finally delivered and used by the tissues is mainly T3. Liothyronine is mildly toxic by ingestion and is an experimental teratogen. When heated to decomposition it emits toxic fumes of NOx, I(-), and Cl(-) (Sax's Dangerous Properties of Industrial Materials).
Regulatory Network
Full List of Protein(s) Regulating This Metabolite
      Amino acid/polyamine transporter (AAPT)
            Integral membrane E16 (SLC7A5) Click to Show/Hide the Full List of Regulating Pair(s):   1 Pair(s)
               Detailed Information Protein   Info click to show the details of this protein
               Regulating Pair Experim Info click to show the details of experiment for validating this pair [1]
                      Introduced Variation Overexpression of SLC7A5
                      Induced Change Liothyronine concentration: increase
                      Summary Introduced Variation         Induced Change 
                      Disease Status Healthy individual
                      Details It is reported that overexpression of SLC7A5 leads to the increase of liothyronine levels compared with control group.
            L-type amino acid transporter 2 (LAT2) Click to Show/Hide the Full List of Regulating Pair(s):   1 Pair(s)
               Detailed Information Protein   Info click to show the details of this protein
               Regulating Pair Experim Info click to show the details of experiment for validating this pair [1]
                      Introduced Variation Overexpression of SLC7A8
                      Induced Change Liothyronine concentration: increase
                      Summary Introduced Variation         Induced Change 
                      Disease Status Healthy individual
                      Details It is reported that overexpression of SLC7A8 leads to the increase of liothyronine levels compared with control group.
      Monocarboxylate porter (MNP)
            Solute carrier family 16 member 2 (SLC16A2) Click to Show/Hide the Full List of Regulating Pair(s): 16 Pair(s)
               Detailed Information Protein   Info click to show the details of this protein
               Regulating Pair (1) Experim Info click to show the details of experiment for validating this pair [1]
                      Introduced Variation Overexpression of SLC16A2
                      Induced Change Liothyronine concentration: increase
                      Summary Introduced Variation         Induced Change 
                      Disease Status Healthy individual ...
                      Details It is reported that overexpression of SLC16A2 leads to the increase of liothyronine levels compared with control group.
               Regulating Pair (2) Experim Info click to show the details of experiment for validating this pair [2]
                      Introduced Variation Overexpression of SLC16A2
                      Induced Change Liothyronine concentration: increase (FC = 4.4)
                      Summary Introduced Variation         Induced Change 
                      Disease Status Healthy individual ...
                      Details It is reported that overexpression of SLC16A2 leads to the increase of liothyronine levels compared with control group.
               Regulating Pair (3) Experim Info click to show the details of experiment for validating this pair [3]
                      Introduced Variation Mutation (S290A) of SLC16A2
                      Induced Change Liothyronine concentration: increase
                      Summary Introduced Variation         Induced Change 
                      Disease Status Hypothyroidism [ICD-11: 5A00]
                      Details It is reported that mutation (S290A) of SLC16A2 leads to the increase of liothyronine levels compared with control group.
               Regulating Pair (4) Experim Info click to show the details of experiment for validating this pair [3]
                      Introduced Variation Mutation (S290F) of SLC16A2
                      Induced Change Liothyronine concentration: increase (FC = 1.85)
                      Summary Introduced Variation         Induced Change 
                      Disease Status Hypothyroidism [ICD-11: 5A00]
                      Details It is reported that mutation (S290F) of SLC16A2 leads to the increase of liothyronine levels compared with control group.
               Regulating Pair (5) Experim Info click to show the details of experiment for validating this pair [2]
                      Introduced Variation Mutation (D453V+pCIneo-hD3) and overexpression of SLC16A2
                      Induced Change Liothyronine concentration: increase (FC = 1.3)
                      Summary Introduced Variation         Induced Change 
                      Disease Status Hypothyroidism [ICD-11: 5A00]
                      Details It is reported that mutation (D453V+pCIneo-hD3) and overexpression of SLC16A2 leads to the increase of liothyronine levels compared with control group.
               Regulating Pair (6) Experim Info click to show the details of experiment for validating this pair [2]
                      Introduced Variation Mutation (D453V+pCIneo-hD3) and overexpression of SLC16A2
                      Induced Change Liothyronine concentration: increase (FC = 1.4)
                      Summary Introduced Variation         Induced Change 
                      Disease Status Hypothyroidism [ICD-11: 5A00]
                      Details It is reported that mutation (D453V+pCIneo-hD3) and overexpression of SLC16A2 leads to the increase of liothyronine levels compared with control group.
               Regulating Pair (7) Experim Info click to show the details of experiment for validating this pair [2]
                      Introduced Variation Mutation (G221R) of SLC16A2
                      Induced Change Liothyronine concentration: increase (FC = 1.2)
                      Summary Introduced Variation         Induced Change 
                      Disease Status Hypothyroidism [ICD-11: 5A00]
                      Details It is reported that mutation (G221R) of SLC16A2 leads to the increase of liothyronine levels compared with control group.
               Regulating Pair (8) Experim Info click to show the details of experiment for validating this pair [2]
                      Introduced Variation Mutation (G282C) of SLC16A2
                      Induced Change Liothyronine concentration: increase (FC = 1.7)
                      Summary Introduced Variation         Induced Change 
                      Disease Status Hypothyroidism [ICD-11: 5A00]
                      Details It is reported that mutation (G282C) of SLC16A2 leads to the increase of liothyronine levels compared with control group.
               Regulating Pair (9) Experim Info click to show the details of experiment for validating this pair [2]
                      Introduced Variation Mutation (G282C+pCIneo-hD3) and overexpression of SLC16A2
                      Induced Change Liothyronine concentration: increase (FC = 1.8)
                      Summary Introduced Variation         Induced Change 
                      Disease Status Hypothyroidism [ICD-11: 5A00]
                      Details It is reported that mutation (G282C+pCIneo-hD3) and overexpression of SLC16A2 leads to the increase of liothyronine levels compared with control group.
               Regulating Pair (10) Experim Info click to show the details of experiment for validating this pair [2]
                      Introduced Variation Mutation (G558D) of SLC16A2
                      Induced Change Liothyronine concentration: increase (FC = 2.3)
                      Summary Introduced Variation         Induced Change 
                      Disease Status Hypothyroidism [ICD-11: 5A00]
                      Details It is reported that mutation (G558D) of SLC16A2 leads to the increase of liothyronine levels compared with control group.
               Regulating Pair (11) Experim Info click to show the details of experiment for validating this pair [2]
                      Introduced Variation Mutation (G558D+pCIneo-hD3) and overexpression of SLC16A2
                      Induced Change Liothyronine concentration: increase (FC = 2.1)
                      Summary Introduced Variation         Induced Change 
                      Disease Status Hypothyroidism [ICD-11: 5A00]
                      Details It is reported that mutation (G558D+pCIneo-hD3) and overexpression of SLC16A2 leads to the increase of liothyronine levels compared with control group.
               Regulating Pair (12) Experim Info click to show the details of experiment for validating this pair [2]
                      Introduced Variation Mutation (InsV236) of SLC16A2
                      Induced Change Liothyronine concentration: increase (FC = 1.2)
                      Summary Introduced Variation         Induced Change 
                      Disease Status Hypothyroidism [ICD-11: 5A00]
                      Details It is reported that mutation (InsV236) of SLC16A2 leads to the increase of liothyronine levels compared with control group.
               Regulating Pair (13) Experim Info click to show the details of experiment for validating this pair [2]
                      Introduced Variation Mutation (InsV236+pCIneo-hD3) and overexpression of SLC16A2
                      Induced Change Liothyronine concentration: increase (FC = 1.5)
                      Summary Introduced Variation         Induced Change 
                      Disease Status Hypothyroidism [ICD-11: 5A00]
                      Details It is reported that mutation (InsV236+pCIneo-hD3) and overexpression of SLC16A2 leads to the increase of liothyronine levels compared with control group.
               Regulating Pair (14) Experim Info click to show the details of experiment for validating this pair [2]
                      Introduced Variation Mutation (P321L) of SLC16A2
                      Induced Change Liothyronine concentration: increase (FC = 1.3)
                      Summary Introduced Variation         Induced Change 
                      Disease Status Hypothyroidism [ICD-11: 5A00]
                      Details It is reported that mutation (P321L) of SLC16A2 leads to the increase of liothyronine levels compared with control group.
               Regulating Pair (15) Experim Info click to show the details of experiment for validating this pair [2]
                      Introduced Variation Mutation (P537L) of SLC16A2
                      Induced Change Liothyronine concentration: increase (FC = 1.5)
                      Summary Introduced Variation         Induced Change 
                      Disease Status Hypothyroidism [ICD-11: 5A00]
                      Details It is reported that mutation (P537L) of SLC16A2 leads to the increase of liothyronine levels compared with control group.
               Regulating Pair (16) Experim Info click to show the details of experiment for validating this pair [2]
                      Introduced Variation Mutation (P537L+pCIneo-hD3) and overexpression of SLC16A2
                      Induced Change Liothyronine concentration: increase (FC = 1.8)
                      Summary Introduced Variation         Induced Change 
                      Disease Status Hypothyroidism [ICD-11: 5A00]
                      Details It is reported that mutation (P537L+pCIneo-hD3) and overexpression of SLC16A2 leads to the increase of liothyronine levels compared with control group.
      Organo anion transporter (OAT)
            Organic anion transporter F (SLCO1C1) Click to Show/Hide the Full List of Regulating Pair(s):   1 Pair(s)
               Detailed Information Protein   Info click to show the details of this protein
               Regulating Pair Experim Info click to show the details of experiment for validating this pair [4]
                      Introduced Variation Overexpression of SLCO1C1
                      Induced Change Liothyronine concentration: increase (FC = 14)
                      Summary Introduced Variation         Induced Change 
                      Disease Status Healthy individual
                      Details It is reported that overexpression of SLCO1C1 leads to the increase of liothyronine levels compared with control group.
References
1 Transport of Iodothyronines by Human L-Type Amino Acid Transporters. Endocrinology. 2015 Nov;156(11):4345-55.
2 Mutations in MCT8 in patients with Allan-Herndon-Dudley-syndrome affecting its cellular distribution. Mol Endocrinol. 2013 May;27(5):801-13.
3 Further Insights into the Allan-Herndon-Dudley Syndrome: Clinical and Functional Characterization of a Novel MCT8 Mutation. PLoS One. 2015 Oct 1;10(10):e0139343.
4 Identification of a novel human organic anion transporting polypeptide as a high affinity thyroxine transporter. Mol Endocrinol. 2002 Oct;16(10):2283-96.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhang and Dr. Mou.